Gilead Sciences’s most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $68.00 short call and a strike $73.00 long call offers a potential 21.36% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $68.00 by expiration. The full premium credit of $0.88 would be kept by the premium seller. The risk of $4.12 would be incurred if the stock rose above the $73.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Will Gilead Sciences Be Able To Continue Its Growth Trajectory?
Mon, 11 Nov 2013 12:59:16 GMT
Seeking Alpha – Shares of Gilead Sciences Inc. ( GILD ) jumped last week when the biotechnology firm reported outstanding third quarter results and also raised its annual forecasts. The revenues of the company were $2.78 …
Merck’s Exciting Anti-Virus Pipeline
Mon, 11 Nov 2013 02:32:02 GMT
Motley Fool – Merck’s got a couple pieces of very promising antiviral news coming down its pipeline. Should investors be getting excited?
Why Don’t These Winning Stocks Pay Dividends?
Sun, 10 Nov 2013 16:34:07 GMT
Motley Fool – Google, Berkshire Hathaway, Amazon.com, and Gilead Sciences are all big enough to pay dividends. Should they?
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
Fri, 08 Nov 2013 13:59:56 GMT
noodls – WASHINGTON–(BUSINESS WIRE)–Nov. 2, 2013– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir …
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
Fri, 08 Nov 2013 13:59:54 GMT
noodls – — Studies Support Efficacy and Safety of an All-Oral Sofosbuvir-Based Regimen for the Preventionand Treatment of Recurrent HCV Infection Following Liver Transplants — WASHINGTON–(BUSINESS WIRE)–Nov. …
Also on Market Tamer…
Follow Us on Facebook